

ABSTRACT OF THE DISCLOSURE

The present invention provides methods of determining aggregation of α -synuclein, which are a hallmark of Lewy body diseases such as Parkinson's disease.

- 5 Also disclosed are inhibitors of the aggregation, including magnesium and α -synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.